Knight Therapeutics Q3 revenue up 32%, beats estimates

Knight Therapeutics

06/11/2025 12:39

Overview

Knight Therapeutics Q3 revenue grows 32% yr/yr, beating analyst expectations

Adjusted EBITDA for Q3 rises 56%, reflecting strong operational performance

Company launched NCIB to purchase up to 3 mln shares over 12 months

Outlook

Knight raises 2025 revenue guidance to C$430 mln - C$440 mln

Company expects adjusted EBITDA to be 13.5% - 14.5% of revenues

Outlook driven by performance of promoted products

Result Drivers

REVENUE GROWTH - Revenue increased 32% yr/yr driven by Paladin and Sumitomo transactions and key promoted products

GROSS MARGIN IMPACT - Gross margin affected by hyperinflation and Paladin transaction expenses

PRODUCT LAUNCHES - New product launches and expanded distribution agreements to drive future growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
C$121.55 mln
C$107 mln (6 Analysts)
Q3 Net Income
-C$3.79 mln
Q3 Operating Expenses
C$55.16 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Knight Therapeutics Inc is C$7.50, about 22.1% above its November 5 closing price of C$5.84

The stock recently traded at 410 times the next 12-month earnings vs. a P/E of 71 three months ago

Press Release: ID:nGNX5m0tkQ

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)